Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) on Monday, soared 6.12% from the previous trading day, before settling in for the closing price of $2.94. Within the past 52 weeks, AMLX’s price has moved between $1.58 and $19.95.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 2300.59% over the past five years. The company achieved an average annual earnings per share of -623.81%. With a float of $41.21 million, this company’s outstanding shares have now reached $67.71 million.
Let’s look at the performance matrix of the company that is accounted for 384 employees.
Amylyx Pharmaceuticals Inc (AMLX) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Amylyx Pharmaceuticals Inc is 39.56%, while institutional ownership is 61.70%. The most recent insider transaction that took place on Sep 30 ’24, was worth 59,429. In this transaction Co-Chief Executive Officer of this company sold 18,589 shares at a rate of $3.20, taking the stock ownership to the 3,120,569 shares. Before that another transaction happened on Sep 30 ’24, when Company’s Co-Chief Executive Officer sold 18,589 for $3.20, making the entire transaction worth $59,414. This insider now owns 3,220,569 shares in total.
Amylyx Pharmaceuticals Inc (AMLX) Latest Financial update
As on 6/30/2024, Multinational firm has announced its last quarter scores, in which it reported 0.3 earnings per share (EPS) for the period falling under the consensus outlook (set at 0.43) by -0.13. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.56 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -623.81% per share during the next fiscal year.
Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) Trading Performance Indicators
Amylyx Pharmaceuticals Inc (AMLX) is currently performing well based on its current performance indicators. A quick ratio of 4.66 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.71.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.45, a number that is poised to hit -0.70 in the next quarter and is forecasted to reach -1.75 in one year’s time.
Technical Analysis of Amylyx Pharmaceuticals Inc (AMLX)
Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) saw its 5-day average volume 0.98 million, a negative change from its year-to-date volume of 2.07 million. As of the previous 9 days, the stock’s Stochastic %D was 36.79%. Additionally, its Average True Range was 0.19.
During the past 100 days, Amylyx Pharmaceuticals Inc’s (AMLX) raw stochastic average was set at 87.78%, which indicates a significant increase from 60.73% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 75.56% in the past 14 days, which was higher than the 70.08% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.41, while its 200-day Moving Average is $5.95. Nevertheless, the first resistance level for the watch stands at $3.21 in the near term. At $3.29, the stock is likely to face the second major resistance level. The third major resistance level sits at $3.43. If the price goes on to break the first support level at $2.99, it is likely to go to the next support level at $2.85. The third support level lies at $2.77 if the price breaches the second support level.
Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) Key Stats
Market capitalization of the company is 212.41 million based on 68,006K outstanding shares. Right now, sales total 380,790 K and income totals 49,270 K. The company made 88,640 K in profit during its latest quarter, and -118,790 K in sales during its previous quarter.
